{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-016862","form_type":"8-K","ticker":"SGHT","cik":"0001531177","company_name":"Sight Sciences, Inc.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.049803+00:00","generated_at":"2026-06-24T00:48:06.517247+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sight Sciences Q2 revenue $17.2M (+37% YoY); net loss $23.8M; FY22 guidance $68-72M","bullets":["Surgical Glaucoma revenue $15.9M (+33% YoY); Dry Eye revenue $1.3M (+143% YoY).","Gross margin expanded to 84% from 82% YoY on manufacturing cost reductions.","Operating expenses rose 75% to $37.4M, driven by personnel and R&D investment.","Cash and equivalents $220.1M; total debt $33.0M as of June 30, 2022.","Full-year 2022 revenue guidance: $68-72M, representing 39-47% growth over 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-016862","json":"https://secwatch.observer/filing/0000950170-22-016862.json","markdown":"https://secwatch.observer/filing/0000950170-22-016862.md","text":"https://secwatch.observer/filing/0000950170-22-016862.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1531177/000095017022016862/0000950170-22-016862-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1531177/000095017022016862/sght-20220811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:48:06.517247+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}